CADTH reviews drugs and makes reimbursement recommendations to Canada's federal, provincial, and territorial public drug programs, with the exception of Quebec, to guide their drug reimbursement decisions.
Provisional Funding Algorithms
CADTH provides advice to the drug programs on the appropriate place in therapy for the drugs within a particular therapeutic area, including the impact of new drugs on the sequencing of treatments for the purposes of reimbursement.
Rapid Response Service
Provides rapid reviews of health technologies to support timely health care decision-making.
Health Technology Assessment Service
Delivers a comprehensive assessment of the clinical and/or economic evidence on health technologies; may include ethical, legal, and social implications.
Optimal Use Service
Delivers a CADTH Health Technology Assessment, with recommendations from an expert panel or committee.
Reviews current health care practices, processes, or protocols to enable a better understanding of the national or international landscape.
Reviews new and emerging health technologies that are likely to have a significant impact on the delivery of health care in Canada.
Offers pharmaceutical companies advice on their early drug development plans from a health technology assessment perspective.